A cross-sectional, comparative, syndromic description of oncological mixed pain in Medical Oncology units in Spain
- 17 Downloads
The reason cancer pain remains prevalent and hard to classify may be partially explained by the failure to identify neuropathic mechanisms. The objective of this research was to identify the syndromes of cancer pain that may be particularly hard to manage due to their mixed pathophysiology.
A series of 384 patients who had cancer of any type, at any stage, and suffered from chronic pain (symptom onset > 3 months) were assessed during a routine return visit in Spain. Medical oncologists indicated the presence and pathophysiology of 33 predefined pain syndromes on a per-patient basis. This information was then measured against clinical, psychosocial, and health care-related data to determine which syndromes pose particular challenges.
The mean (standard deviation) age of patients was 61.6 (12.6) years, 49.7% were women. Most (82%) had advanced metastatic disease, 68.7% were on second-line or palliative therapies. The worst syndrome was nociceptive, pure neuropathic, and mixed in 34.6, 26.9, and 38.6% of patients, respectively. Any syndrome could be of mixed pathophysiology. Only 10 syndromes were common (≥ 5% of patients). Syndromes related to malignant bone pain and involvement of chest wall structures were the most frequent. Certain syndromes (including tumor-related bone pain, chemotherapy-induced peripheral neuropathies, paraneoplastic pain syndromes, and malignant neuralgias or injury to cranial nerves) can be particularly challenging when they have a mixed pathophysiology, because the neuropathic component is rarely or unevenly considered.
Virtually all cancer pain syndromes can present mixed pathophysiology. Certain syndromes can include neuropathic components that are frequently overlooked.
KeywordsCancer Classification Chronic pain Neoplasms Neuralgia Pathophysiology
The authors wish to thank all the clinical investigators for their contribution to this study in recruiting, assessing, and providing the data from the patients. The authors acknowledge the contribution made by Raquel Jerez (Biostatistician) during the statistical analysis of the data. Authors wish also to thank patients who consented to participate and release their personal data for the scientific purposes of this research.
Santiago Ponce developed the protocol, performed clinical evaluations of patients, and supervised the study.
Ana Yuste was the top recruiter and performed clinical evaluations.
Ana Esquivias and Ana Leal developed the protocol and coordinated the study.
Jesús Villoria participated in protocol development, designed and performed the analysis of data, and drafted the manuscript.
All authors participated in the review and extraction of literature, the design of the study, the interpretation of results, and the preparation of the manuscript. All authors had full access to the data and have provided their final approval to the manuscript for publication.
This research has been funded by Grünenthal Pharma, S.A. Grünenthal Pharma, S.A. did not have any direct corporate role in the design, analysis, and interpretation of results, or preparation of the manuscript.
Compliance with ethical standards
Authors received funds from Grünenthal Pharma, S.A. for this research.
Santiago Ponce and Ana Yuste have no competing interests to declare.
Ana Esquivias and Ana Leal have a full time position at Grünenthal Pharma, S.A.
Jesús Villoria has received honoraria for drafting manuscripts for Grünenthal Pharma, Mundipharma, and Esteve and receives consultancy fees from Grünenthal Pharma, Lilly, Novartis, Esteve, Amadix, and Vivia Biotech.
The study was performed in accordance with the updated Declaration of Helsinki. The Ethics Committee of the Hospital Doce de Octubre in Madrid approved the study protocol prior to start.
All patients provided a written informed consent to participate.
- 9.Kaasa S, Apolone G, Klepstad P, Loge JH, Hjermstad MJ, Corli O, Strasser F, Heiskanen T, Costantini M, Zagonel V, Groenvold M, Fainsinger R, Jensen MP, Farrar JT, McQuay H, Rothrock NE, Cleary J, Deguines C, Caraceni A, European Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care Research Network (EAPCRN) (2011) Expert conference on cancer pain assessment and classification—the need for international consensus: working proposals on international standards. BMJ Support Palliat Care 1:281–287CrossRefGoogle Scholar
- 10.Rayment C, Hjermstad MJ, Aass N, Kaasa S, Caraceni A, Strasser F, Heitzer E, Fainsinger R, Bennett MI, On behalf of the European Palliative Care Research Collaborative (EPCRC) (2013) Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study. Palliat Med 27:714–721CrossRefGoogle Scholar
- 12.Brunelli C, Bennett MI, Kaasa S, Fainsinger R, Sjøgren P, Mercadante S, Løhre ET, Caraceni A, European Association for Palliative Care (EAPC) Research Network, International Association for the Study of Pain (IASP) Cancer Pain Special Interest Group (2014) Classification of neuropathic pain in cancer patients: a Delphi expert survey report and EAPC/IASP proposal of an algorithm for diagnostic criteria. Pain 155:2707–2713CrossRefGoogle Scholar
- 14.Merskey H (2009) The taxonomy of pain. In: Smith HS (ed) Current therapy in pain, 1st edn. Saunders Elsevier, Philadelphia, pp 1–4Google Scholar
- 17.Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giamberardino MA, Kaasa S, Kosek E, Lavandʼhomme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JW, Wang SJ et al (2015) A classification of chronic pain for ICD-11. Pain 156:1003–1007PubMedPubMedCentralGoogle Scholar
- 20.Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E (2005) Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114:29–36CrossRefGoogle Scholar
- 21.Cleeland CS (2009) The Brief Pain Inventory user guide. The University of Texas M.D. Anderson Cancer Center, HoustonGoogle Scholar
- 25.NCCN Panel Members (2018) Adult cancer pain. National Comprehensive Cancer Network, Fort WashingtonGoogle Scholar
- 26.Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM, Ferrell BR, Loscalzo M, Meier DE, Paice JA, Peppercorn JM, Somerfield M, Stovall E, von Roenn JH (2012) American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol 30:880–887CrossRefGoogle Scholar
- 28.Mulvey MR, Rolke R, Klepstad P, Caraceni A, Fallon M, Colvin L, Laird B, Bennett MI, IASP Cancer Pain SIG and the EAPC Research Network (2014) Confirming neuropathic pain in cancer patients: applying the NeuPSIG grading system in clinical practice and clinical research. Pain 155:859–863CrossRefGoogle Scholar
- 29.Garcia de Paredes ML, del Moral Gonzalez F, Martinez del Prado P, Marti Ciriquian JL, Enrech Frances S, Cobo Dols M, Esteban Gonzalez E, Ortega Granados AL, Majem Tarruella M, Cumplido Buron JD, Gasco Hernandez A, Lopez Miranda E, Ciria Santos JP, de Castro Carpeno FJ (2011) First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the on study. Ann Oncol 22:924–930CrossRefGoogle Scholar